1. Home
  2. ALHC vs ACAD Comparison

ALHC vs ACAD Comparison

Compare ALHC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alignment Healthcare Inc.

ALHC

Alignment Healthcare Inc.

HOLD

Current Price

$21.76

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.47

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALHC
ACAD
Founded
2013
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.8B
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
ALHC
ACAD
Price
$21.76
$22.47
Analyst Decision
Buy
Buy
Analyst Count
8
22
Target Price
$23.13
$30.55
AVG Volume (30 Days)
3.3M
1.3M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
69.12
EPS
N/A
2.30
Revenue
$3,948,719,000.00
$726,437,000.00
Revenue This Year
$33.69
$18.80
Revenue Next Year
$24.74
$11.70
P/E Ratio
$405.00
$9.64
Revenue Growth
46.06
40.45
52 Week Low
$11.63
$14.45
52 Week High
$23.87
$28.35

Technical Indicators

Market Signals
Indicator
ALHC
ACAD
Relative Strength Index (RSI) 62.70 52.81
Support Level $19.93 $20.80
Resistance Level $22.87 $22.97
Average True Range (ATR) 0.70 0.60
MACD 0.04 0.08
Stochastic Oscillator 68.56 77.87

Price Performance

Historical Comparison
ALHC
ACAD

About ALHC Alignment Healthcare Inc.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: